Literature DB >> 11453955

GH administration and discontinuation in healthy elderly men: effects on body composition, GH-related serum markers, resting heart rate and resting oxygen uptake.

K H Lange1, F Isaksson, M H Rasmussen, A Juul, J Bülow, M Kjaer.   

Abstract

BACKGROUND AND OBJECTIVES: GH administration results in increased lean body mass (LBM), decreased fat mass (FM) and increased energy expenditure (EE). GH therapy may therefore have potential benefits, especially in the elderly, who are known to have decreased function of the GH/IGF-I axis. Several studies have focused on effects of GH administration in the elderly in the last decade. However, very limited information is available regarding changes in body composition and EE upon GH discontinuation in the elderly. The present study therefore investigated the effects of 12 weeks of GH administration and subsequent discontinuation on body composition, resting oxygen uptake (VO2), resting heart rate (HR) and GH related serum markers in healthy elderly men. SUBJECTS AND METHODS: Sixteen healthy men [age 74 +/- 1 years (mean +/- SEM), height 174.2 +/- 1.6 cm, body weight 80.7 +/- 2.6 kg, body fat 27.5 +/- 1.1%] completed the study protocol. Recombinant human GH (1.80 +/- 0.24 IU/day) was administered for 12 weeks in a single-blinded, placebo-controlled design. Body composition (dual energy X-ray absorptiometry), resting VO2 (indirect calorimetry), resting HR (telemetry) and serum IGF-I, IGF-II, IGFBP-3 and acid labile subunit (ALS) were measured at baseline, after 12 weeks of GH administration and, additionally in the GH group, 1, 2, 3, 4, 5 and 9 days after GH discontinuation.
RESULTS: Body weight was unchanged from baseline to 12 weeks in both groups. However, GH administration caused a decrease in FM (3.4 +/- 1.0 kg, P < 0.012), paralleled by a similar increase in LBM (3.2 +/- 0.4 kg, P < 0.0002). Resting VO2 and resting HR increased by 31 +/- 3.6% and 7.3 +/- 1.9 per minute, respectively, in the GH-group, where significant increases in serum IGF-I, IGFBP-3 and ALS also were noted. None of the above parameters changed in the placebo group. Within 2-3 days after GH discontinuation, the GH related serum markers and resting HR returned to baseline levels, whereas resting VO2 remained elevated even 9 days after GH discontinuation. In addition, GH discontinuation caused a significant decrease in body weight (1.86 +/- 0.35 kg), derived exclusively from a decrease in LBM (1.63 +/- 0.43 kg), while the decreased FM was maintained (12 weeks: 17.93 +/- 1.65 kg, +9 days: 17.74 +/- 1.62 kg).
CONCLUSIONS: The increases in serum IGF-I, IGFBP-3, ALS and resting heart rate induced by 12 weeks of GH administration in elderly men returned to baseline levels within 2-3 days after GH discontinuation. However, resting VO2 remained elevated for a longer period. GH administration reduced fat mass but maintained body weight by increasing lean body mass. In contrast, 9 days of GH discontinuation reduced body weight exclusively by reducing lean body mass.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11453955     DOI: 10.1046/j.1365-2265.2001.01344.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  9 in total

Review 1.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

2.  Supra-physiological rhGH administration induces gender-related differences in the hypothalamus-pituitary-thyroid (HPT) axis in healthy individuals.

Authors:  P Sgrò; M Sansone; A Parisi; A Sartorio; A Sansone; F Romanelli; A Lenzi; L Di Luigi
Journal:  J Endocrinol Invest       Date:  2016-05-26       Impact factor: 4.256

Review 3.  Claims for the anabolic effects of growth hormone: a case of the emperor's new clothes?

Authors:  M J Rennie
Journal:  Br J Sports Med       Date:  2003-04       Impact factor: 13.800

Review 4.  Muscle tissue changes with aging.

Authors:  Elena Volpi; Reza Nazemi; Satoshi Fujita
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2004-07       Impact factor: 4.294

Review 5.  Frailty, osteoporosis and hip fracture: causes, consequences and therapeutic perspectives.

Authors:  Y Rolland; G Abellan van Kan; A Bénétos; H Blain; M Bonnefoy; P Chassagne; C Jeandel; M Laroche; F Nourhashémi; P Orcel; F Piette; C Ribot; P Ritz; C Roux; J Taillandier; F Trémollières; G Weryha; B Vellas
Journal:  J Nutr Health Aging       Date:  2008-05       Impact factor: 4.075

Review 6.  Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives.

Authors:  Y Rolland; S Czerwinski; G Abellan Van Kan; J E Morley; M Cesari; G Onder; J Woo; R Baumgartner; F Pillard; Y Boirie; W M C Chumlea; B Vellas
Journal:  J Nutr Health Aging       Date:  2008 Aug-Sep       Impact factor: 4.075

7.  Tendon and skeletal muscle matrix gene expression and functional responses to immobilisation and rehabilitation in young males: effect of growth hormone administration.

Authors:  A P Boesen; K Dideriksen; C Couppé; S P Magnusson; P Schjerling; M Boesen; M Kjaer; H Langberg
Journal:  J Physiol       Date:  2013-09-30       Impact factor: 5.182

Review 8.  Aging and the growth hormone/insulin like growth factor-I axis.

Authors:  Mark Sherlock; Andrew A Toogood
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

Review 9.  Growth hormone doping: a review.

Authors:  Ioulietta Erotokritou-Mulligan; Richard Ig Holt; Peter H Sönksen
Journal:  Open Access J Sports Med       Date:  2011-07-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.